Treatment of children with chronic kidney disease and proteinuria
Conditions
Brief summary
Number of participants with treatment emergent adverse events (TEAEs), Change in serum potassium levels from baseline to Day 540±7, Change in systolic blood pressure (SBP) from baseline to Day 540±7
Detailed description
Change in urinary protein-to-creatinine ratio (UPCR) and urinary albumin-to-creatinine ratio (UACR) from baseline to Day 540±7, Change in estimated glomerular filtration rate (eGFR) from baseline to Day 540±7
Interventions
Sponsors
Bayer AG
Eligibility
Sex/Gender
All
Age
0 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with treatment emergent adverse events (TEAEs), Change in serum potassium levels from baseline to Day 540±7, Change in systolic blood pressure (SBP) from baseline to Day 540±7 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in urinary protein-to-creatinine ratio (UPCR) and urinary albumin-to-creatinine ratio (UACR) from baseline to Day 540±7, Change in estimated glomerular filtration rate (eGFR) from baseline to Day 540±7 | — |
Countries
Austria, Belgium, Bulgaria, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Netherlands, Poland, Portugal, Spain, Sweden
Outcome results
None listed